XML 36 R22.htm IDEA: XBRL DOCUMENT
v3.23.1

Note 14 - Segment Data | 12 Months Ended
--- | ---
Mar. 31, 2023
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 14. Segment Data Segment information is prepared on the same basis that our CEO and chief operating decision maker uses to manage our segments, evaluate financial results, and make key operating decisions. Our four reportable segments are organized primarily by the nature of the goods and services they sell. When determining our reportable segments, we aggregated operating segments based on their similar economic and operating characteristics. We evaluate the performance of our operating segments based on revenues, organic revenues growth, and gross profit. The accounting policies of the operating segments are the same as those described in Note 1. "Description of Business and Summary of Significant Accounting Policies." The following tables set forth our segment information:
|  | Year Ended March 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenues (a): |  |  |  |  |  |  |  |  |  |  |  |
Clinical Genomics |  | $ | 62,299 |  |  | $ | 32,840 |  |  | $ | - |
Sterilization and Disinfection Control |  |  | 64,609 |  |  |  | 59,044 |  |  |  | 53,119 |
Biopharmaceutical Development |  |  | 47,365 |  |  |  | 45,579 |  |  |  | 33,892 |
Calibration Solutions |  |  | 44,807 |  |  |  | 46,872 |  |  |  | 46,926 |
Reportable segment revenues |  |  | 219,080 |  |  |  | 184,335 |  |  |  | 133,937 |
Corporate and Other (b) |  |  | - |  |  |  | - |  |  |  | - |
Total revenues |  | $ | 219,080 |  |  | $ | 184,335 |  |  | $ | 133,937 |
Gross profit: |  |  |  |  |  |  |  |  |  |  |  |
Clinical Genomics |  | $ | 32,485 |  |  | $ | 11,941 |  |  | $ | - |
Sterilization and Disinfection Control |  |  | 46,520 |  |  |  | 43,720 |  |  |  | 39,870 |
Biopharmaceutical Development |  |  | 30,340 |  |  |  | 28,605 |  |  |  | 21,035 |
Calibration Solutions |  |  | 24,388 |  |  |  | 24,989 |  |  |  | 26,112 |
Reportable segment gross profit |  |  | 133,733 |  |  |  | 109,255 |  |  |  | 87,017 |
Corporate and Other (b) |  |  | (40 | ) |  |  | (165 | ) |  |  | (3 | )
Gross profit |  | $ | 133,693 |  |  | $ | 109,090 |  |  | $ | 87,014 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |
Operating expenses |  |  | 130,373 |  |  |  | 104,388 |  |  |  | 74,656 |
Operating income |  |  | 3,320 |  |  |  | 4,702 |  |  |  | 12,358 |
Nonoperating expense |  |  | 3,709 |  |  |  | 1,128 |  |  |  | 10,055 |
Earnings before income taxes |  | $ | (389 | ) |  | $ | 3,574 |  |  | $ | 2,303 |
| (a) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
| (b) | Unallocated corporate expenses and other business activities are reported within Corporate and Other.
The following table sets forth net inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.
|  | March 31, |  |  | March 31, |
|  | 2023 |  |  | 2022 |
Clinical Genomics |  | $ | 13,985 |  |  | $ | 11,802 |
Sterilization and Disinfection Control |  |  | 3,492 |  |  |  | 2,176 |
Biopharmaceutical Development |  |  | 8,384 |  |  |  | 4,495 |
Calibration Solutions |  |  | 8,781 |  |  |  | 6,133 |
Reportable segment inventory |  |  | 34,642 |  |  |  | 24,606 |
Corporate and Other |  |  | - |  |  |  | - |
Total inventories, net |  | $ | 34,642 |  |  | $ | 24,606 |
The following table sets forth a summary of long-lived assets by geographic area. Long-lived assets exclude goodwill and intangible assets acquired in a business combination and deferred tax assets.
|  | As of March 31, |
|  | 2023 |  |  | 2022 |
United States |  | $ | 34,729 |  |  | $ | 36,475 |
Foreign |  |  | 3,793 |  |  |  | 3,975 |
Total |  | $ | 38,522 |  |  | $ | 40,450 |
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows:
|  | Year Ended March 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
United States |  | $ | 117,281 |  |  | $ | 99,068 |  |  | $ | 71,387 |
China |  |  | 25,797 |  |  |  | 16,518 |  |  |  | 6,612 |
Other |  |  | 76,002 |  |  |  | 68,749 |  |  |  | 55,938 |
Total revenues |  | $ | 219,080 |  |  | $ | 184,335 |  |  | $ | 133,937 |
No customer accounts for 10% or more of our consolidated revenues. No foreign country other than China exceeds 10% of total revenues.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration